PULS’s board consists of extensive scientific, industrial, business, legal and financial experience and expertise.

Ragnar Lindqvist - Chairman

Lawyer, member of the Swedish Bar Association. Chairman of Innovum Invest AB, ISEC Industrial Security AB, Pyramid Communication AB, Henry och Gerda Dunkers Foundation, Henry och Gerda Dunkers Donationsfond nr 2, Henry Dunkers Förvaltnings AB, ARMEC Lindebergs Foundation, OV Helsingborg HK and P.U.L.S. AB. Board member of Anocca AB, Trioplast Industrier AB, Crafoordska Foundation and Stig and Ragna Gorthons Foundation.

Jörgen Johnsson - Deputy Chairman

Former CEO of Pharmacia Consumer Healthcare worldwide, Senior Vice President of Pharmacia Corporation and member of Pharmacia’s Executive Management Group from 1995-2000. Founder of P.U.L.S. AB,  PULS partner and board member of Laccure AB. Innovator in multiple PULS project companies.

Marie Lidgard

Senior Partner Lavindia AB, a lawyer by training with extensive experience of the financial services industry. Her experience includes MD of the Swedish Investment Fund Association and Senior Vice President of Nordea Investment Management. Lidgard has also been involved with recruitment and worked for the Swedish Ministry of Industry, where she was responsible for recruiting board members to state owned companies. In recent years, Lidgard has been active as an investor and founder of a number of new enterprises, and is currently on the board of six companies and organizations.

Michael Oredsson

Michael Oredsson has close to twenty years experience as CEO of life science companies in Sweden, Australia and Norway and serves, or has served, as Chairman of the board or board member of several companies. During the eighties and nineties he worked in leading management positions in companies such as Pharmacia, M&M/Mars and Nestlé.
Michael is a graduate of Lund University in International Business Administration.

Olov Sterner

M.Sc, PhD, Professor in Organic Chemistry, Faculty of Science, Lund University. Major research fields are biologically active secondary metabolites and medicinal chemistry. Author or co-author of more than 420 publications in scientific journals, 30 patents/patent applications, and 5 text books in organic chemistry/chemical toxicology. Board member of P.U.L.S. AB and Glactone Pharma AB. Innovator in multiple PULS project companies.

Karin Wingstrand

M.Sc. Pharmacy with extensive senior experience of pharmaceutical research and development from roles such as Global Head and Vice President Clinical Development within AstraZeneca and Global Head and Vice President Pharmaceutical and Analytical R&D, AstraZeneca. Presently board member and advisor in life science. Board member of Adenovir Pharma AB.